Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

Metric
Company Name	Medigene AG
Symbol	MDG1
MSH ID	COM:MEDIGENE
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	DE
Stage
Employee Count	76
Website	medigene.com
LinkedIn
Founders

Metric
Market Cap	35.71M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	6.53M
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.23M
EBITDA	-16.26M
Operating Income	-17.84M
Net Income	-17.50M
EPS	-0.71
Diluted EPS	-0.71
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.78
Operating Profit Margin	-2.43
EBITDA Margin	-2.49
Net Profit Margin	-2.50
Return on Equity	-0.61
Return on Assets	-0.53
Return on Capital Employed	-0.68

COM:MEDIGENE

Medigene AG

Last Close

1.55

31/03 15:36

Market Cap

33.01M

Beta: -

Volume Today

158.72K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-4.28
P/B Ratio	0.96
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.02
EV Multiple	-1.36

Metric
Days Sales Outstanding
Days Payables Outstanding	116.70
Days Inventory Outstanding	122.88
Operating Cycle	163.40
Cash Conversion Cycle	149.73
Asset Turnover	0.29

Metric
Operating Cash Flow	-16.36M
Free Cash Flow	-17.07M
Cash Flow to Debt	-4.36
Operating Cash Flow/Sales	-1.67
Free Cash Flow Yield	0.31

Metric
Cash & Equivalents	9.38M
Accounts Receivable	2.77M
Inventory	1.08
Goodwill
Debt to Capitalization	0.12
Debt to Assets	0.07
Current Ratio	5.02
Quick Ratio	4.40

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.91
SG&A to Revenue	0.16